These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8911668)

  • 41. Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in MPTP-treated cynomolgus monkeys.
    Kuno S; Mizuta E; Sakamoto H; Ichihara K; Nagasaka M
    Clin Neuropharmacol; 1998; 21(1):35-40. PubMed ID: 9579283
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of the dopamine agonist cabergoline in the treatment of movement disorders.
    Marco AD; Appiah-Kubi LS; Chaudhuri KR
    Expert Opin Pharmacother; 2002 Oct; 3(10):1481-7. PubMed ID: 12387694
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias.
    Kordower JH; Vinuela A; Chu Y; Isacson O; Redmond DE
    J Comp Neurol; 2017 Feb; 525(3):498-512. PubMed ID: 27418401
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Mov Disord; 2006 Jan; 21(1):9-17. PubMed ID: 16127720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
    Bibbiani F; Costantini LC; Patel R; Chase TN
    Exp Neurol; 2005 Mar; 192(1):73-8. PubMed ID: 15698620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
    Porter MC; Appiah-Kubf LS; Chaudhuri KR
    Int J Clin Pract; 2002; 56(6):468-74. PubMed ID: 12166546
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.
    Ouattara B; Gasparini F; Morissette M; Grégoire L; Samadi P; Gomez-Mancilla B; Di Paolo T
    J Neurochem; 2010 May; 113(3):715-24. PubMed ID: 20132464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
    Grégoire L; Morin N; Ouattara B; Gasparini F; Bilbe G; Johns D; Vranesic I; Sahasranaman S; Gomez-Mancilla B; Di Paolo T
    Parkinsonism Relat Disord; 2011 May; 17(4):270-6. PubMed ID: 21315648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BDNF levels are not related with levodopa-induced dyskinesias in MPTP monkeys.
    Samadi P; Morissette M; Lévesque D; Di Paolo T
    Mov Disord; 2010 Jan; 25(1):116-21. PubMed ID: 20014115
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.
    Bibbiani F; Oh JD; Chase TN
    Neurology; 2001 Nov; 57(10):1829-34. PubMed ID: 11723272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys.
    Stephenson DT; Meglasson MD; Connell MA; Childs MA; Hajos-Korcsok E; Emborg ME
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1257-66. PubMed ID: 15980058
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys.
    Samadi P; Morissette M; Calon F; Hadj Tahar A; Dridi M; Belanger N; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2008 Feb; 62(2):101-9. PubMed ID: 17992687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys.
    Grondin R; Doan VD; Grégoire L; Bédard PJ
    Neurology; 1999 Mar; 52(4):771-6. PubMed ID: 10078726
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
    Jenner P
    Neurology; 2002 Feb; 58(4 Suppl 1):S1-8. PubMed ID: 11909980
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The rationale for the use of dopamine agonists in Parkinson's disease.
    Jenner P
    Neurology; 1995 Mar; 45(3 Suppl 3):S6-12. PubMed ID: 7715795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.